This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Currently Amended) A pharmaceutical preparation comprising active compound, <u>5 mg</u> gelatin as a binder and fillers and which is free of organic solvent, wherein the active compound is levo-thyroxine sodium, and which preparation is in tablet form.

Claim 2. (Canceled)

- Claim 3. (**Previously Presented**) The pharmaceutical preparation according to claim 1, containing 5 to 400 µg of levothyroxine.
- Claim 4. (**Previously Presented**) The pharmaceutical preparation according to claim 1, containing levothyroxine sodium micronized with a particle size of between 5 μ m and 25 μ m.
- Claim 5. (**Previously Presented**) The pharmaceutical preparation according to Claim 1, wherein the filler is lactose, maize starch or microcrystalline cellulose.

Claim 6. - 8. (Cancelled)

- Claim 9. (**Currently Amended**) A pharmaceutical preparation comprising levothyroxine sodium, <u>5 mg</u> gelatin as a binder and fillers which is free of organic solvent and which is in solid form.
- Claim 10. (**Currently Amendded**) A pharmaceutical preparation comprising active compound, <u>5 mg</u> gelatin as a binder and fillers and which is free of organic solvent wherein the active compound consists essentially of levo-thyroxine sodium and liothyronine sodium, and

2

which preparation is in solid form.

- Claim 11. (**Previously Presented**) The pharmaceutical preparation according to claim 9, containing 5 to 400 µg of levothyroxine.
- Claim 12. (**Previously Presented**) The pharmaceutical preparation according to claim 9, containing levothyroxine sodium micronized with a particle size of between 5 μ m and 25 μ m.
- Claim 13. (**Previously Presented**) The pharmaceutical preparation according to claim 9, wherein the filler is lactose, maize starch or microcrystalline cellulose.
- Claim 14. (**Previously Presented**) The pharmaceutical preparation according to claim 10, containing 5 to 400 µg of levothyroxine.
- Claim 15. (**Previously Presented**) The pharmaceutical preparation according to claim 10, containing levothyroxine sodium micronized with a particle size of between 5 μ m and 25 μ m.
- Claim 16 (**Previously Presented**) The pharmaceutical preparation according to claim 10, wherein the filler is lactose, maize starch or microcrystalline cellulose.
- Claim 17. (**Previously Presented**) The pharmaceutical preparation according to claim 9, comprising levothyroxine sodium, lactose, starch, gelatin, croscarmellose sodium, and magnesium stearate.
- Claim 18. (**Currently Amended**) the <u>The</u> pharmaceutical preparation according to claim 17, further comprising liothyronine sodium.